Cancer biologists at EPFL, UNIGE, and the German Cancer Research Center (Heidelberg) have developed a novel immunotherapy that does not require knowledge of a tumor’s antigenic makeup. The new results may pave the way to first-in-kind clinical applications.
Unfortunately, tumors often erect barriers against the body’s immune system, allowing them to grow uncontrolled. This setback, called immunosuppression, may involve the inhibition of DCs and their ability to present tumor antigens to CD8+ T cells.
Addressing the limitations of traditional vaccines
Over the last few decades, researchers have worked to overcome tumor-induced immunosuppression by various strategies, collectively called immunotherapies, some of which are approved treatments effective in patients with certain cancers.
One approach is to generate DCs from the blood monocytes (a type of immune white blood cells) of a patient with cancer, expose them in the laboratory to defined tumor-derived material from a tumor biopsy (antigen loading step), and then reintroduce them into the patient’s body. This procedure, often referred to as a DC vaccine, is expected to significantly enhance the presentation of tumor antigens to CD8+ T cells.
However, DC vaccines have produced mixed results in clinical trials. One potential limitation is the use of monocyte-derived DCs. These cells lack certain essential properties of naturally occurring DCs, such as type I DCs (cDC1), which play a crucial role in activating CD8+ T cells.
Another potential shortcoming is its dependence on the antigen loading step, which uses predefined antigens that may not represent the full spectrum of relevant antigens present in cancer cells. Addressing the limitations of traditional DC vaccines could enhance their therapeutic efficacy.
A team of scientists led by Michele De Palma, associate professor in the School of Life Sciences and director of the Agora Cancer Research Center, has now developed engineered DCs with the capacity to differentiate into cDC1 and to stimulate anti-tumor immunity when transferred to mice with tumors, without the need for antigen loading step. The study is published in Nature Cancer.
“Our strategy does not use the monocyte-derived DCs employed in previous studies, but relies on a population of DC progenitors, called DCPs, which we can produce in vitro in the laboratory from readily available sources, such as blood and bone marrow,” De Palma explains.
Surpassing the outcomes
When engineered to express two immune-stimulatory molecules (IL-12 and FLT3L), the DCP could initiate effective anti-tumor immune responses in various cancer models, surpassing the outcomes achieved with other traditional DC formulations. “Remarkably, the engineered DCPs worked in the absence of antigen loading, which implies that they could be potentially effective against a broad range of human cancers, so irrespective of the antigens that they express.”
The ability of engineered DCPs to broadly engage multiple components of the immune system, not limited to CD8+ T cells, may explain their effectiveness. “A very promising result was the ability of the DCPs to unlock the efficacy of CAR-T cells in eradicating brain tumors in mice,” says Professor Denis Migliorini, head of neuro-oncology at UNIGE and one of the study’s authors.
CAR-T cells are another class of engineered immune cells already approved for the treatment of certain tumors, but their efficacy in brain cancer has so far been limited. “We are committed to combining DCPs with CAR-T cells in patients with incurable brain cancer,” adds Migliorini.
“Our preclinical results require further development and testing before moving to clinical application,” cautions De Palma. DCPs can be readily obtained from human blood, which should facilitate the translation of preclinical results into a potentially transformative cancer immunotherapy.
More information: Ali Ghasemi et al, Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy, Nature Cancer (2023). DOI: 10.1038/s43018-023-00668-y
News
Where do nanoparticles go once they enter the body?
New international best practice guidance, co-written at ANSTO, sets out how to measure where nanoparticles like titanium dioxide end up in the body and how long they remain. The guidance has been shared by [...]
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People
A major African trial suggests that changing how HIV treatment is delivered could significantly improve viral suppression in adolescents. Young people with HIV were more likely to keep the virus suppressed when they received [...]
WHO Factsheets – The top 10 causes of death
In 2023, the 10 leading causes of death accounted for 33 million deaths, or 54% of the total 61 million deaths worldwide. The top global causes of death, in order of total number of lives lost, [...]
Aging Cells May Be Hiding From the Immune System – Scientists Think They Know How
Your immune system is supposed to clear out damaged cells. Researchers may have found how some of them hide and linger as the body ages. Researchers led by Cedars-Sinai Health Sciences University have identified [...]
Your Voice May Reveal How Fast Your Brain Is Aging
Researchers have developed a machine-learning “speech clock” that estimates age from subtle patterns in how people speak and what they say. It is possible that people’s voices may contain certain signals of aging that [...]
Optogenetics Pioneers Win 2026 Nobel Prize in Physiology or Medicine
The 2026 Nobel Prize in Physiology or Medicine has been awarded to Peter Hegemann, Georg Nagel, and Karl Deisseroth for the development of optogenetics, a revolutionary technology that uses light to control individual neurons [...]
Molecular Manufacturing: The Future of Nanomedicine – From NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
What is ‘American Covid’ and how bad is it?
Cases of so-called ‘American Covid’ are on the rise in the UK. The strain is officially called XFG, or ‘Stratus’, and is the most common variant in North America, hence the name. It might soon [...]
Researcher at Russian plague laboratory dies of ‘unknown’ infection
Russian authorities have imposed "anti-epidemic measures" after a laboratory worker at an institute in Siberia dedicated to studying the plague and other infectious diseases died of a mysterious illness. The researcher, a 28-year-old female [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
A Surprising Brain Signal Could Explain Why Eating Less Protein Extends Lifespan
A new paper suggests that limiting protein intake triggers a coordinated response throughout the body that may help explain how protein restriction affects healthy aging. Animals respond to protein restriction, or reduced protein in [...]
Back and shoulder surgery is often worse than useless
Millions of operations should be scrapped SIX IN TEN Britons have surgery at some point. So do lots of Americans, at a cost of perhaps $500bn a year, a third of all spending on [...]
Cocaine plays with mind, hijacks brain circuit, drives increasingly rigid and repetitive behavior
Researchers have found that cocaine hijacks brain circuit, which to drive increasingly rigid and repetitive behavior. The brain circuit that normally participates in selecting natural mouth and face movements, but which becomes disproportionately engaged [...]
Injectable nanodevices could provide effective treatment for drug-resistant glioblastoma
The brain cancer glioblastoma is one of the most aggressive and treatment-resistant cancers known to medicine, carrying a median survival of just 12-15 months, even with the best available care. Now, researchers at the [...]
New Treatment Cuts “Bad” Cholesterol in Half for a Full Year
A single infusion of an experimental CRISPR-Cas9 therapy was reported to safely lower LDL cholesterol by 52.5% and triglycerides by 47.8%, as measured 12 months after treatment. What if one infusion could keep cholesterol [...]
Too Much RNA Can Drain a Cell’s Energy, Scientists Discover
A virus may cripple a cell’s power supply simply by producing too much of a molecule the cell needs to survive. New research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences [...]
